[미국특허]
Antibodies relating to PIVKA-II and uses thereof
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
G01N-033/53
C07K-016/00
C07K-016/36
C07K-016/44
G01N-033/574
출원번호
US-0843490
(2010-07-26)
등록번호
US-9120862
(2015-09-01)
발명자
/ 주소
Yoshimura, Toru
Dowell, Barry Lee
Beligere, Gangamani S.
Yoshida, Eisaku
출원인 / 주소
ABBOTT LABORATORIES
대리인 / 주소
Reininger, Irene M.
인용정보
피인용 횟수 :
0인용 특허 :
35
초록
The present disclosure relates to antibodies and immunoassay methods for use in the diagnosis, treatment and prevention of hepatocellular carcinoma (HCC), liver cancer and related conditions.
대표청구항▼
1. A method of detecting PIVKA-II antigen in a test sample, the method comprising the steps of: a) contacting the test sample with a monoclonal antibody having an antigen binding portion that binds to an epitope within amino acids 1-13 of PIVKA-II and for a time and under conditions sufficient for t
1. A method of detecting PIVKA-II antigen in a test sample, the method comprising the steps of: a) contacting the test sample with a monoclonal antibody having an antigen binding portion that binds to an epitope within amino acids 1-13 of PIVKA-II and for a time and under conditions sufficient for the formation of monoclonal antibody-antigen complexes; and b) detecting the presence of the monoclonal antibody-antigen complexes, wherein the presence of the monoclonal antibody-antigen complexes indicates the presence of PIVKA-II in the test sample, wherein the monoclonal antibody is a monoclonal antibody produced by a hybridoma cell line having ATCC deposit designation PTA-10541. 2. The method of claim 1, wherein the test sample is whole blood, serum or plasma. 3. The method of claim 1, wherein the monoclonal antibody is labeled with a detectable label and wherein (b) comprises measuring the signal generated by or emitted from the detectable label and detecting the PIVKA-II antigen in the test sample. 4. The method of claim 3, wherein the detectable label is selected from the group consisting of a radioactive label, an enzymatic label, a chemiluminescent label, a fluorescence label, a thermometric label, and an immuno-polymerase chain reaction label. 5. The method of claim 3, wherein the detectable label is an acridinium compound. 6. The method of claim 1, further comprising: a) generating or providing a source of hydrogen peroxide to the antibody-antigen complexes; b) adding a basic solution to the mixture of step (a); and c) measuring the light signal generated or emitted in step (b) and detecting PIVKA-II in the sample. 7. A method of detecting PIVKA-II antigen in a test sample comprising the steps of: a) contacting the test sample with a first monoclonal antibody having an antigen binding portion that binds to an epitope within amino acids 13-27 of PIVKA-II, for a time and under conditions sufficient for the formation of first monoclonal antibody-antigen complexes; b) adding a second monoclonal antibody to the first monoclonal antibody/antigen complexes, wherein the second monoclonal antibody has an antigen binding portion that binds to an epitope within amino acids 1-13 of PIVKA-II and is conjugated to a detectable label, for a time and under conditions sufficient to form first monoclonal antibody/antigen/second monoclonal antibody complexes; and c) measuring the signal generated by or emitted from the detectable label and detecting the PIVKA-II antigen in the test sample, wherein the second monoclonal antibody is a monoclonal antibody produced by a hybridoma cell line having ATCC deposit designation PTA-10541. 8. The method of claim 7, wherein the first monoclonal antibody is a monoclonal antibody produced by a hybridoma cell line having ATCC deposit designation PTA-9638. 9. The method of claim 7, wherein the test sample is whole blood, serum or plasma. 10. The method of claim 7, wherein the detectable label is selected from the group consisting of a radioactive label, an enzymatic label, a chemiluminescent label, a fluorescence label, a thermometric label, and an immuno-polymerase chain reaction label. 11. The method of claim 7, wherein the detectable label is an acridinium compound. 12. The method of claim 7, wherein the first monoclonal antibody is immobilized on a solid phase either before or after the formation of the first monoclonal antibody-antigen complexes. 13. A method of detecting PIVKA-II antigen in a test sample comprising the steps of: a) contacting the test sample with 1) a PIVKA-II reference antigen, wherein the reference antigen is attached to a detectable label capable of generating a detectable signal and 2) a monoclonal antibody to PIVKA-II antigen, for a time and under conditions sufficient to form PIVKA-II reference antigen/monoclonal antibody complexes; b) detecting a signal generated by the detectable label, wherein the amount of PIVKA-II antigen detected in the test sample is inversely proportional to the amount of PIVKA-II reference antigen bound to the monoclonal antibody, wherein the monoclonal antibody comprises an antigen-binding domain that binds to an epitope within amino acids 1-13 of PIVKA-II, wherein the monoclonal antibody is produced by a hybridoma cell line having ATCC deposit designation PTA-10541. 14. The method of claim 13, wherein the test sample is whole blood, serum or plasma. 15. The method of claim 13, wherein the detectable label is selected from the group consisting of a radioactive label, an enzymatic label, a chemiluminescent label, a fluorescence label, a thermometric label, and an immuno-polymerase chain reaction label. 16. The method of claim 13, wherein the detectable label is an acridinium compound. 17. A method for determining an amount of PIVKA-II in a sample comprising: a) contacting the test sample with at least two different binding proteins for a time and under conditions sufficient to form first binding protein/antigen/second binding protein complexes, wherein each binding protein comprises an antigen binding portion that specifically binds to a subset of amino acids 1-33 of PIVKA-II, wherein the antigen binding portion of each binding protein binds to a different subset of amino acids 1-33 of PIVKA-II, and wherein at least one of the binding proteins is conjugated to a detectable label; b) measuring the signal generated by or emitted from the detectable label; and c) determining the amount of PIVKA-II in the sample based on the signal, wherein the binding proteins are monoclonal antibodies, wherein a first monoclonal antibody has an antigen binding portion that binds to PIVKA-II, and a second monoclonal antibody has an antigen binding portion that binds to PIVKA-II and an antigen binding portion that binds to at least a subset of amino acids 1-33 of prothrombin, wherein the first monoclonal antibody has an antigen binding portion that binds to amino acids 13-27 of PIVKA-II, and the second monoclonal antibody has an antigen binding portion that binds to amino acids 1-13 of PIVKA-II, wherein the first monoclonal antibody is an antibody produced by the hybridoma cell line designated by American Type Culture Collection (ATCC) deposit designation PTA-9638, and the second monoclonal antibody is an antibody produced by the hybridoma cell line designated by American Type Culture Collection (ATCC) deposit PTA-10541.
Edwards David A. ; Caponetti Giovanni,ITX ; Hrkach Jeffrey S. ; Lotan Noah,ILX ; Hanes Justin ; Ben-Jebria Abdell Aziz ; Langer Robert S., Aerodynamically light particles for pulmonary drug delivery.
Goldstein Joyce A. ; De Morais Sonia M.F., Cloning, expression and diagnosis of human cytochrome P450 2C19: the principal determinant of s-mephenytoin metabolism.
Lee Hye-Jung ; Johnson OluFunmi L. ; Zale Stephen E. ; Tracy Mark A., Composition and method using solid-phase particles for sustained in vivo release of a biologically active agent.
Winter Gregory Paul (Cambridge GB3) Duncan Alexander Robert (Wimbledon GBX) Burton Dennis Raymond (Sheffield GB3), DNA encoding antibodies with altered effector functions.
Platz Robert M. ; Patton John S. ; Foster Linda C. ; Eljamal Mohammed,LBX, Dispersible antibody compositions and methods for their preparation and use.
Balazs Endre A. (Ft. Lee NJ) Leshchiner Adolf (Fairview NJ) Larsen Nancy E. (Ridgefield Park NJ), Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same.
Khalil Omar S. (Libertyville IL) Hanna Charles F. (Libertyville IL) Zurek Thomas F. (River Forest IL) Grigalauski Denise A. (Wildwood IL), Immunoassay device with liquid transfer between wells by washing.
Morgan Jeffrey R. (Brighton MA) Mulligan Richard C. (Cambridge MA), In vivo introduction and expression of foreign genetic material in epithelial cells.
Khalil Omar S. (Libertyville IL) Zurek Thomas F. (River Forest IL) Genger Kevin R. (Chicago IL) Pepe Curtis J. (McHenry IL) Jou Yi-Her (Vernon Hills IL) Cotter Stephen M. (Fox Lake IL), Method and apparatus for heterogeneous chemiluminescence assay.
Cozzette Stephen N. (Hightstown NJ) Davis Graham (Plainsboro NJ) Itak Jeanne (Hamilton NJ) Lauks Imants R. (Yardley PA) Mier Randall M. (Ottawa NJ CAX) Piznik Sylvia (Jackson NJ) Smit Nicolaas (Hight, Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor.
Bernstein Howard (Cambridge MA) Morrel Eric (Needham MA) Mathiowitz Edith (Brookline MA) Schwaller Kirsten (Duxbury MA) Beck Thomas R. (Concord MA), Protein microspheres and methods of using them.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.